Register by March 13th and SAVE $300*!
(Mention Promo Code: JZT974)
RegisterRequest BrochureView Website
Conference Chairman: Tony Dutta, Senior Vice President of Operations, IDISElite Speakers Include: Zareen Ahmed, Corporate Regulatory Affairs-Regulatory CMC, sanofi-aventis David Bernstein, Ph.D., Consultant, Bernstein CMC Regulatory Consulting Christina Butta, Senior Principal Scientist, Pfizer Inc Tiffany Cavallaro, Clinical Supply Planning Manager, Merck Scott Eaton, Regulatory CMC, Pfizer Inc Jim Krupa, Associate Director, Planning and Coordination, Cephalon Micheline Marshall, Director, Clinical Pharmacy, Wyeth Gail Owens, Corporate Regulatory Affairs-RCMC, sanofi-aventis Frank Reale, Associate Director, Worldwide Regulatory Coordination and Clinical Supplies, Merck John Simmons, CMC Consultant; Former Director, Office of New Drug Quality Assessment, FDA Mark Ware, Director, Clinical Trial Services, IDIS Jill Wechsler, Washington Editor, Pharmaceutical Executive Yolanda Bell, Global NAMP Business Process Owner, Amgen Chris Wilson, Chief Operating Officer, Keats Healthcare Ltd
www.cbinet.com/comparator
The First and Only Source for Invaluable Information on:
Market Dynamics Driving an Increase in Comparator Studies and Keys to Success
Selection:Register by 3/13/09 Standard
2-Day Conference $1695$1995
Conference Co-Sponsor:
http://www.idispharma.com/
2009 Sponsors:
http://www.myoderm.com/, http://www.myoderm.com/, http://www.almacgroup.com/pharmaservices/, http://www.adiramedica.com/, http://www.pharmarama.com/about.htm, http://www.bilcare.com/, http://www.keatshealthcare.co.uk/, http://www.multipharma.ch/
Offer not valid on workshop only or academic registrations.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.